Systemic Mitochondrial Disease

The ubiquity of mitochondria renders any organ susceptible to mitochondrial disease, thereby manifesting clinical features that are heterogeneous and often resembling various systemic diseases. With our interdisciplinary approach and state-of-the-art facilities, Protheragen offers a comprehensive range of specialized services tailored to support researchers and institutions in their pursuit of unraveling the complexities surrounding mitochondrial diseases.

The current state of basic research and treatment for mitochondrial diseases is severely limited, underscoring the critical importance of conducting comprehensive studies in this field. Protheragen acknowledges the pressing need for interdisciplinary collaboration and cutting-edge research to address these challenges effectively. By providing specialized services tailored to support researchers and institutions, our aim is to pave the way for advancements in this field. From Alpers Disease to MNGIE, the diverse spectrum of mitochondrial diseases underscores the necessity for comprehensive studies and innovative treatments.

Our Services

At Protheragen, we acknowledge the critical necessity for comprehensive solutions to address the diverse spectrum of mitochondrial disorders. From small molecule drugs to gene therapies, our offerings encompass a broad range of interventions aimed at addressing systemic mitochondrial diseases.

Small Molecule Drug Development Service

Our small molecule drug development service facilitates the identification and optimization of compounds targeting mitochondrial dysfunction, offering tailored solutions from target identification to preclinical studies to expedite small molecule drug discovery and development.

Macromolecular Drug Development Service

Our macromolecular drug development service specializes in the design and optimization of intricate therapeutics, encompassing enzyme replacement therapies and therapeutic antibodies, to effectively tackle the distinctive challenges posed by mitochondrial diseases.

Cell Therapy Development Service

Our cell therapy development service utilizes the potential of cell-based approaches for the treatment of mitochondrial diseases, ranging from stem cell transplantation to gene-modified cell therapies.

Gene Therapy Development Service

The focus of our gene therapy development service lies in the advancement of gene-based therapeutics, encompassing gene replacement and gene editing techniques, with the aim to rectify genetic defects that underlie mitochondrial disorders.

Our Advantages

Professional Team

Advanced Technologies

Customized Solutions

Competitive Pricing

With Protheragen' comprehensive range of services, we are dedicated to advancing research on mitochondrial diseases and translating scientific discoveries into tangible therapeutic solutions. Feel free to contact us today for assistance in supporting your research endeavors.

For research use only, not for clinical use.